BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
And, you know, the predominant reason was because they weren't eligible to receive it. And then there's also a group of patients that we think are not T2. And then we do the surgery and they are. And they are really high risk, higher than T2. So I think for those patients, adjuvant checkpoint inhibitor is still an important treatment option.
0
💬
0
Comments
Log in to comment.
There are no comments yet.